<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02132598</url>
  </required_header>
  <id_info>
    <org_study_id>13-182</org_study_id>
    <nct_id>NCT02132598</nct_id>
  </id_info>
  <brief_title>Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases</brief_title>
  <official_title>A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liza Villaruz, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label phase II clinical trial designed to allow a preliminary assessment of&#xD;
      the efficacy and safety of cabozantinib in unselected Non-Small Cell Lung Cancer (NSCLC)&#xD;
      patients with metastases to the brain and in the subset of patients with c-MET amplified&#xD;
      Non-Small Cell Lung Cancer with metastases to the brain. Previously treated patients with&#xD;
      non-squamous NSCLC who have had brain metastases at any point in their treatment history are&#xD;
      eligible for enrollment on this clinical trial. Patients with clinically asymptomatic&#xD;
      untreated brain metastases will be allowed on trial at the discretion of the treating&#xD;
      investigator. Patients who have undergone treatment for their brain metastases with&#xD;
      Whole-Brain Radiation Therapy (WBRT), stereotactic radiosurgery (SRS) or surgery must be&#xD;
      clinically stable and recovered from all procedures at the time of study enrollment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, single-arm, open-label study of cabozantinib in subjects with molecularly&#xD;
      unselected Non-Small Cell Lung Cancer (NSCLC) with metastases to the brain and in patients&#xD;
      with c-MET amplified Non-Small Cell Lung Cancer (NSCLC) with metastases to the brain.&#xD;
&#xD;
      Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until&#xD;
      disease progression, death or unacceptable adverse events. Treatment cycles are 4 weeks in&#xD;
      duration.&#xD;
&#xD;
      The primary endpoint is Overall Response Rate (ORR) in both the unselected NSCLC population&#xD;
      and the molecularly selected patients on the basis of c-MET amplification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial stopped due to slow patient accrual.&#xD;
  </why_stopped>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">August 9, 2019</completion_date>
  <primary_completion_date type="Actual">August 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The proportion of response-evaluable patients who achieve Complete Response (CR) or Partial Response (PR) as best response by RECIST v1.1 criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Proportion of response-evaluable patients that experienced Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) as best response (RECIST v1.1 criteria) per the total study population criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Stable Disease (SD) is defined as, neither sufficient shrinkage (compared to baseline) to qualify for partial or complete response (CR or PR) nor sufficient increase (taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest) to qualify for progressive disease (PD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Progression-free survival is the time measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression), whichever occurs first, with progression defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The length of time from the start of treatment that patients remain alive, until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Until disease progression; Up to 2 years</time_frame>
    <description>Time from initiation of study treatment to disease progression per RECIST v1.1, excluding death from causes unrelated to the disease. As defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Grade of Adverse Events Reported</measure>
    <time_frame>From baseline up to 20 weeks</time_frame>
    <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Grade of AE at Least Possibly Related to Treatment Reported</measure>
    <time_frame>From baseline up to 20 weeks</time_frame>
    <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Grade of AE at Least Probably Related to Treatment Reported</measure>
    <time_frame>From baseline up to 20 weeks</time_frame>
    <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Grade of AE Definitely Related to Treatment Reported:</measure>
    <time_frame>From baseline up to 20 weeks</time_frame>
    <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Non Small Cell Lung Cancer (NSCLC)</condition>
  <condition>Metastases to the Brain</condition>
  <arm_group>
    <arm_group_label>Cabozantinib (XL184)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events.&#xD;
Treatment cycles are 4 weeks in duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabozantinib</intervention_name>
    <arm_group_label>Cabozantinib (XL184)</arm_group_label>
    <other_name>Cometriq</other_name>
    <other_name>EXEL-7184</other_name>
    <other_name>EXEL-02977184</other_name>
    <other_name>CAS Registry# 1140909-48-3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previously treated patients with non-squamous NSCLC who have had brain metastases at&#xD;
             any point in their treatment history are eligible for enrollment on this clinical&#xD;
             trial. (Patients must have received at least one regimen for systemic disease which&#xD;
             may be cytotoxic or oral tyrosine kinase inhibitor therapy.)&#xD;
&#xD;
               -  Patients with clinically asymptomatic untreated brain metastases will be allowed&#xD;
                  on trial at the discretion of the treating physician&#xD;
&#xD;
               -  Patients who have undergone treatment for their brain metastases with whole brain&#xD;
                  radiotherapy, stereotactic radiosurgery, or surgical resection must be clinically&#xD;
                  stable and recovered from all procedures at the time of study enrollment.&#xD;
&#xD;
          2. Patients must have tumor tissue available for submission that is sufficient to&#xD;
             complete c-MET Fluorescence in Situ Hybridization (FISH) studies as well as routine&#xD;
             molecular profiling at the UPMC. Patients must agree to submission of these specimens&#xD;
             as defined in Section 9.&#xD;
&#xD;
               -  c-MET amplification will be determined by FISH ratio (c-MET/CEP7) &gt; 2.0, based on&#xD;
                  testing of the primary tumor and/or site of metastatic disease&#xD;
&#xD;
               -  Patients' tumors must undergo testing for Epidermal Growth Factor Receptor (EGFR)&#xD;
                  exon 19 deletion, EGFR exon 21 L858R substitution, and anaplastic lymphoma kinase&#xD;
                  (ALK) rearrangements. If positive, patients must have been treated with an&#xD;
                  appropriate tyrosine kinase inhibitors (TKI) prior to enrolling to the study.&#xD;
&#xD;
          3. The subject has had an assessment of all extracranial disease sites (e.g., by&#xD;
             computerized tomography (CT) scan, positron emission tomography-CT, and bone scan as&#xD;
             appropriate) within 28 days before the first dose of cabozantinib.&#xD;
&#xD;
          4. The subject must have a baseline brain MRI scan or CT scan of the head (in patients&#xD;
             unable to obtain an MRI) within 14 days prior to first dose of cabozantinib.&#xD;
&#xD;
               -  Patients receiving glucocorticoids must be on a stable dose of glucocorticoids&#xD;
                  during the 5 days prior to the baseline brain imaging.&#xD;
&#xD;
          5. Patients must have measurable disease as defined by Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) v1.1&#xD;
&#xD;
          6. Subjects having undergone recent resection or biopsy of an intracranial tumor will be&#xD;
             eligible as long as all of the following conditions apply:&#xD;
&#xD;
               -  First dose of cabozantinib occurs at least 28 days after surgery, and the subject&#xD;
                  has recovered from the effects of surgery&#xD;
&#xD;
          7. Age ≥18 years&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%)&#xD;
&#xD;
          9. Patients must have normal organ and marrow function as defined below: (within 4 days&#xD;
             of beginning treatment unless noted otherwise)&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥1,500/mm3 (no CSF support)&#xD;
&#xD;
               -  Platelets ≥100,000/mm3&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Bilirubin (Gilbert's Disease) &lt; 3.0 mg/dL&#xD;
&#xD;
               -  Aspartate Aminotransferase (AST) (SGOT) ≤3.0 × ULN&#xD;
&#xD;
               -  Alanine Aminotransferase (ALT) (SGPT) ≤3.0 × ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               -  Creatinine clearance (CrCl) ≥40 mL/min&#xD;
&#xD;
               -  For creatinine clearance estimation, the Cockcroft and Gault equation should be&#xD;
                  used:&#xD;
&#xD;
               -  Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72)&#xD;
&#xD;
               -  Female: Multiply above result by 0.85 ≤ 1.5 x ULN&#xD;
&#xD;
               -  Lipase (no radiologic or clinical evidence of pancreatitis) &lt; 2.0 x ULN&#xD;
&#xD;
               -  Urine protein/creatinine ratio (UPCR) ≤1&#xD;
&#xD;
               -  Serum phosphorus, calcium, magnesium and potassium ≥ LLN&#xD;
&#xD;
         10. The subject is capable of understanding and complying with the protocol requirements&#xD;
             and has signed the informed consent document.&#xD;
&#xD;
         11. Women of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening.&#xD;
&#xD;
         12. The effects of cabozantinib on the developing human fetus are unknown. For this reason&#xD;
             women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             4 months after the last dose of study drug, even if oral contraceptives are used.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has received cytotoxic chemotherapy (including investigational cytotoxic&#xD;
             chemotherapy) or biologic agents (e.g., cytokines or antibodies; including&#xD;
             investigational biologic agents) within 3 weeks, or nitrosoureas/ mitomycin C within 6&#xD;
             weeks before the first dose of study treatment.&#xD;
&#xD;
          2. The subject has received prior treatment with a small molecule kinase inhibitor or a&#xD;
             hormonal therapy (including investigational kinase inhibitors or hormones) within 14&#xD;
             days or five half-lives of the compound or active metabolites, whichever is longer,&#xD;
             before the first dose of study treatment.&#xD;
&#xD;
          3. Prior treatment with cabozantinib or other c-MET directed therapy.&#xD;
&#xD;
          4. The subject has received radiation therapy as follows:&#xD;
&#xD;
               -  To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of&#xD;
                  study treatment or has with ongoing complications or is without complete recovery&#xD;
                  and healing from prior radiation therapy&#xD;
&#xD;
               -  To bone or brain metastasis within 14 days of the first dose of study treatment&#xD;
&#xD;
               -  To any other site(s) within 28 days of the first dose of study treatment&#xD;
&#xD;
          5. The subject has received radionuclide treatment within 6 weeks of the first dose of&#xD;
             study treatment.&#xD;
&#xD;
          6. The subject has evidence of acute intracranial or intratumoral hemorrhage either by&#xD;
             MRI or computerized tomography (CT) scan. The subject has not recovered to baseline or&#xD;
             CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia and other&#xD;
             non-clinically significant AEs.&#xD;
&#xD;
          7. The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or partial&#xD;
             thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 7 days before the&#xD;
             first dose of study treatment.&#xD;
&#xD;
          8. The subject is receiving concomitant treatment with warfarin, warfarin-related agents,&#xD;
             or low molecular weight heparin (LMWH) at the time of study entry at therapeutic&#xD;
             doses. Low-dose warfarin (≤ 1 mg/day) or LMWH at prophylactic doses are permitted.&#xD;
&#xD;
          9. The subject has received enzyme-inducing anti-epileptic agents within 2 weeks before&#xD;
             the first dose of cabozantinib (e.g., carbamazepine, phenytoin, phenobarbital,&#xD;
             primidone). Other enzyme inducing agents prohibited within 2 weeks before the first&#xD;
             dose of cabozantinib include rifampin, rifabutin, rifapentin, and St. John's Wort.&#xD;
&#xD;
         10. The subject has experienced any of the following:&#xD;
&#xD;
               -  Clinically-significant gastrointestinal bleeding within 6 months before the first&#xD;
                  dose of study treatment b.Hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood&#xD;
                  within 3 months before the first dose of study treatment&#xD;
&#xD;
               -  Any other signs indicative of pulmonary hemorrhage within 3 months before the&#xD;
                  first dose of study treatment&#xD;
&#xD;
         11. The subject has radiographic evidence of cavitating pulmonary lesion(s)&#xD;
&#xD;
         12. The subject has tumor abutting, invading or encasing any major blood vessels.&#xD;
&#xD;
         13. The subject has evidence of tumor invading the Gastro Intestinal (GI) tract&#xD;
             (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of&#xD;
             endotracheal or endobronchial tumor within 28 days before the first dose of&#xD;
             cabozantinib.&#xD;
&#xD;
         14. The subject has uncontrolled, significant intercurrent or recent illness including,&#xD;
             but not limited to, the following conditions:&#xD;
&#xD;
               -  Cardiovascular disorders including:&#xD;
&#xD;
                    -  Congestive heart failure (CHF): New York Heart Association (NYHA) Class III&#xD;
                       (moderate) or Class IV (severe) at the time of screening&#xD;
&#xD;
                    -  Concurrent uncontrolled hypertension defined as sustained BP &gt; 140 mm Hg&#xD;
                       systolic, or &gt; 90 mm Hg diastolic despite optimal antihypertensive treatment&#xD;
                       within 7 days of the first dose of study treatment&#xD;
&#xD;
                    -  Any history of congenital long QT syndrome&#xD;
&#xD;
                    -  Any of the following within 6 months before the first dose of study&#xD;
                       treatment:&#xD;
&#xD;
        1.unstable angina pectoris 2.clinically-significant cardiac arrhythmias 3.stroke (including&#xD;
        Transient Ischemic Attack (TIA), or other ischemic event) 4.myocardial infarction (MI)&#xD;
        5.thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous&#xD;
        filter (e.g. vena cava filter) are not eligible for this study)&#xD;
&#xD;
          -  Gastrointestinal disorders particularly those associated with a high risk of&#xD;
             perforation or fistula formation including:&#xD;
&#xD;
          -  Any of the following within 28 days before the first dose of study treatment&#xD;
&#xD;
               1. Intra-abdominal tumor/metastases invading GI mucosa&#xD;
&#xD;
               2. Active peptic ulcer disease,&#xD;
&#xD;
               3. Inflammatory bowel disease (including ulcerative colitis and Crohn's disease),&#xD;
                  diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis&#xD;
&#xD;
               4. Malabsorption syndrome&#xD;
&#xD;
          -  Any of the following within 6 months before the first dose of study treatment:&#xD;
&#xD;
               1. Abdominal fistula&#xD;
&#xD;
               2. Gastrointestinal perforation&#xD;
&#xD;
               3. Bowel obstruction or gastric outlet obstruction&#xD;
&#xD;
               4. Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess&#xD;
                  must be confirmed prior to initiating treatment with cabozantinib even if the&#xD;
                  abscess occurred more than 6 months before the first dose of study treatment.&#xD;
&#xD;
          -  Other disorders associated with a high risk of fistula formation including&#xD;
             Percutaneous Endoscopic Gastrostomy (PEG) tube placement within 3 months before the&#xD;
             first dose of study therapy.&#xD;
&#xD;
          -  Other clinically significant disorders such as:&#xD;
&#xD;
               -  Serious active infection requiring systemic treatment within 28 days before the&#xD;
                  first dose of study treatment.&#xD;
&#xD;
               -  Serious non-healing wound/ulcer/bone fracture within 28 days before the first&#xD;
                  dose of study treatment.&#xD;
&#xD;
               -  History of organ transplant&#xD;
&#xD;
               -  Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days&#xD;
                  before the first dose of study treatment.&#xD;
&#xD;
          -  History of surgery as follows:&#xD;
&#xD;
               1. Subjects having undergone recent resection or biopsy of an intracranial tumor&#xD;
                  will be eligible as long as all of the following conditions apply: First dose of&#xD;
                  cabozantinib occurs at least 28 days after surgery, and the subject has recovered&#xD;
                  from the effects of surgery.&#xD;
&#xD;
               2. Other minor surgery within 28 days of the first dose of cabozantinib if there&#xD;
                  were no wound healing complications. If there is evidence of wound dehiscence,&#xD;
                  subjects will be eligible for trial after a minimum of 3 months after surgery to&#xD;
                  the first dose of cabozantinib, provided complete wound healing is confirmed at&#xD;
                  least 28 days before the first dose of cabozantinib.&#xD;
&#xD;
               3. Other major surgery within 2 months of the first dose of cabozantinib if there&#xD;
                  were no wound healing complications. If there is evidence of wound dehiscence,&#xD;
                  subjects will be eligible for trial after a minimum of 6 months after surgery to&#xD;
                  the first dose of cabozantinib, provided complete wound healing in confirmed at&#xD;
                  least 28 days before the first dose of cabozantinib.&#xD;
&#xD;
               4. The subject is unable to swallow tablets.&#xD;
&#xD;
               5. The subject has a corrected QT interval calculated by the Fridericia formula&#xD;
                  (QTcF) &gt;500 ms within 28 days before randomization. Note: if initial QTcF is&#xD;
                  found to be &gt; 500 ms, two additional EKGs separated by at least 3 minutes should&#xD;
                  be performed. If the average of these three consecutive results for QTcF is ≤ 500&#xD;
                  ms, the subject meets eligibility in this regard.&#xD;
&#xD;
               6. The subject is pregnant or breastfeeding.&#xD;
&#xD;
               7. The subject has a previously identified allergy or hypersensitivity to components&#xD;
                  of the study treatment formulation.&#xD;
&#xD;
               8. The subject is unable or unwilling to abide by the study protocol or cooperate&#xD;
                  fully with the investigator or designee.&#xD;
&#xD;
               9. The subject has had evidence within 2 years of the start of study treatment of&#xD;
                  another malignancy which required systemic treatment. Note: Subjects with a&#xD;
                  history of early stage or locally advanced non-metastatic prostate cancer within&#xD;
                  2 years of the start of study treatment may be included in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liza Villaruz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPCI Department Hematology-Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute- Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Liza Villaruz, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Non Small Cell</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>c-MET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02132598/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cabozantinib (XL184)</title>
          <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cabozantinib (XL184)</title>
          <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" lower_limit="51.0" upper_limit="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>c-MET amplification</title>
          <description>c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. Over-expression of c-Met protein has been associated with poor prognosis in some solid tumors.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ADENOCARCINOMA IN SITU, NOS</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ADENOCARCINOMA, NOS</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NON-SMALL CELL CA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Disease</title>
          <description>Stage 0. Cancer in situ; the cancer is only located in the place of origin.&#xD;
Stage I. Small tumor with no deep growth into surrounding tissues; no spread to the lymph nodes or other body parts.&#xD;
Stage II and Stage III. Larger cancers or tumors that have grown more deeply into surrounding tissue and may have spread to lymph nodes (only).&#xD;
Stage IV. Cancer has spread to other body organs (metastasis).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stage IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage l-III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response</title>
        <description>The proportion of response-evaluable patients who achieve Complete Response (CR) or Partial Response (PR) as best response by RECIST v1.1 criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Patients evaluable for response: Received at least one dose of study drug, and, underwent at least one radiologic scan follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabozantinib (XL184)</title>
            <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response</title>
          <description>The proportion of response-evaluable patients who achieve Complete Response (CR) or Partial Response (PR) as best response by RECIST v1.1 criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.</description>
          <population>Patients evaluable for response: Received at least one dose of study drug, and, underwent at least one radiologic scan follow-up.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.006" upper_limit=".806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <description>Proportion of response-evaluable patients that experienced Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) as best response (RECIST v1.1 criteria) per the total study population criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Stable Disease (SD) is defined as, neither sufficient shrinkage (compared to baseline) to qualify for partial or complete response (CR or PR) nor sufficient increase (taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest) to qualify for progressive disease (PD).</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>As no patients who received at least one dose of study drug and underwent at least one follow-up radiologic scan were able to be evaluated later than 15 weeks, this endpoint cannot be assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabozantinib (XL184)</title>
            <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR)</title>
          <description>Proportion of response-evaluable patients that experienced Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) as best response (RECIST v1.1 criteria) per the total study population criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Stable Disease (SD) is defined as, neither sufficient shrinkage (compared to baseline) to qualify for partial or complete response (CR or PR) nor sufficient increase (taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest) to qualify for progressive disease (PD).</description>
          <population>As no patients who received at least one dose of study drug and underwent at least one follow-up radiologic scan were able to be evaluated later than 15 weeks, this endpoint cannot be assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival is the time measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression), whichever occurs first, with progression defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Only one patient was assessed as having disease progression.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabozantinib (XL184)</title>
            <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival is the time measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression), whichever occurs first, with progression defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.</description>
          <population>Only one patient was assessed as having disease progression.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>The length of time from the start of treatment that patients remain alive, until death from any cause.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>&quot;All patients&quot; includes all 5 of the patients for whom survival data were available, regardless of c-MET status. &quot;c-MET positive patients&quot; (only) does not include patients for who c-MET status was not positive.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabozantinib (XL184)</title>
            <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>The length of time from the start of treatment that patients remain alive, until death from any cause.</description>
          <population>&quot;All patients&quot; includes all 5 of the patients for whom survival data were available, regardless of c-MET status. &quot;c-MET positive patients&quot; (only) does not include patients for who c-MET status was not positive.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All patients</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" lower_limit="3.09" upper_limit="NA">Upper bound of 95% CI not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c-MET positive patients (only)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="0.43" upper_limit="NA">Upper bound of 95% CI not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP)</title>
        <description>Time from initiation of study treatment to disease progression per RECIST v1.1, excluding death from causes unrelated to the disease. As defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.</description>
        <time_frame>Until disease progression; Up to 2 years</time_frame>
        <population>Only one participant experienced disease progression.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabozantinib (XL184)</title>
            <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>Time from initiation of study treatment to disease progression per RECIST v1.1, excluding death from causes unrelated to the disease. As defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.</description>
          <population>Only one participant experienced disease progression.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Grade of Adverse Events Reported</title>
        <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
        <time_frame>From baseline up to 20 weeks</time_frame>
        <population>Patients that received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabozantinib (XL184)</title>
            <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Grade of Adverse Events Reported</title>
          <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
          <population>Patients that received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Grade of AE at Least Possibly Related to Treatment Reported</title>
        <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
        <time_frame>From baseline up to 20 weeks</time_frame>
        <population>Patients that received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabozantinib (XL184)</title>
            <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Grade of AE at Least Possibly Related to Treatment Reported</title>
          <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
          <population>Patients that received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Grade of AE at Least Probably Related to Treatment Reported</title>
        <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
        <time_frame>From baseline up to 20 weeks</time_frame>
        <population>Patients that received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabozantinib (XL184)</title>
            <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Grade of AE at Least Probably Related to Treatment Reported</title>
          <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
          <population>Patients that received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Grade of AE Definitely Related to Treatment Reported:</title>
        <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
        <time_frame>From baseline up to 20 weeks</time_frame>
        <population>Patients that received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabozantinib (XL184)</title>
            <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Grade of AE Definitely Related to Treatment Reported:</title>
          <description>Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.</description>
          <population>Patients that received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days after discontinuation of treatment.</time_frame>
      <desc>Serious Adverse Events are defined as grade 3 and higher toxicity events, per CTCAE v4.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Cabozantinib (XL184)</title>
          <description>Cabozantinib - 60 mg orally, once daily (4 weeks treatment cycles)&#xD;
Treatment until disease progression, death or unacceptable adverse events.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Stadterman, MPH MCCR</name_or_title>
      <organization>UPMC Hillman Cancer Center</organization>
      <phone>412-647-5554</phone>
      <email>stadtermanbm@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

